Remarkably, concomitant inhibition of VM (using a specific FAK inhibitor) with “classical” anti-angiogenesis treatment with bevacizumab, resulted in the improved control of uveal melanoma in vivo tumor growth. This evidence concerns the gene PTK2 and uveal melanoma.